Publications by authors named "Nathan Grellier"

Colorectal cancer (CRC) is a worldwide public health issue specifically in patients with chronic diseases associated with a western lifestyle, such as metabolic diseases and inflammatory bowel diseases (IBD). Interestingly, both metabolic disorders and IBD are characterized by a chronic state of inflammation that contributes to the carcinogenesis with specific alteration of the gut microbiota composition and function. Evidence now shows that this altered gut microbiota contributes fueling a chronic pro-inflammatory state in a vicious circle that can favor CRC development.

View Article and Find Full Text PDF

Background: Early complicated Crohn's disease (CD) may require ileal resection as first-line treatment.

Aim: To evaluate the long-term outcomes of patients who underwent early ileal resection.

Methods: We conducted a retrospective study in two inflammatory bowel diseases (IBD) referral centres, including patients with ileocaecal resection and segmental ileal resection within 5 years of CD diagnosis.

View Article and Find Full Text PDF

Crohn's disease (CD) is a chronic disease of the digestive tract whose pathogenesis remains not fully understood. Several studies have implicated the gut microbiota as a key player in the onset of gut inflammation. However, most of the data is based on case-control studies comparing patients with established disease with controls, usually healthy individuals.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the effectiveness and safety of JAK inhibitors and S1P receptor modulators for treating chronic antibiotic-refractory pouchitis (CARP), as there is limited data on this.
  • Data from 15 patients were analyzed, revealing that after 3 months of treatment with JAK inhibitors, 53.3% had a clinical response and 40% achieved clinical remission, with some patients showing improvements after 12 months.
  • No side effects were reported, suggesting that these small molecules could be a promising option for CARP patients who haven’t responded to other biologic therapies, warranting further research.
View Article and Find Full Text PDF
Article Synopsis
  • Intestinal dysbiosis, which is a disruption in the gut microbiota, is linked to inflammatory bowel disease (IBD) and the study aims to explore the role of acyl-homoserine lactones (AHL), which are bacterial signaling molecules, in this condition.
  • Using data from the Inflammatory Bowel Disease Multi'omics Database, the study found no AHL synthase genes but identified several putative receptor genes, with specific receptors being under-expressed in IBD patients, particularly those with Crohn's disease.
  • The research suggests that targeting LuxR receptors involved in bacterial quorum sensing could be a promising strategy to influence gut microbiota and potentially treat IBD.
View Article and Find Full Text PDF

Bacteria are known to communicate with each other and regulate their activities in social networks by secreting and sensing signaling molecules called autoinducers, a process known as quorum sensing (QS). This is a growing area of research in which we are expanding our understanding of how bacteria collectively modify their behavior but are also involved in the crosstalk between the host and gut microbiome. This is particularly relevant in the case of pathologies associated with dysbiosis or disorders of the intestinal ecosystem.

View Article and Find Full Text PDF